Figure 4

Evaluation of omeprazole and saline treated SJL/J mice with EAE. Quantitation of percent of naïve, CM or EM CD4+ or CD8+ cells (relative to respective parent CD4+ or CD8+ populations) was performed on spleen cells from saline (n = 5) and omeprazole (n = 5) treated SJL/J mice during active disease (A, B). No significant differences were observed following omeprazole treatment compared to saline in the relative percentages of all T cell populations examined. Average clinical scores (C) and weight difference from the day prior to disease onset (D) in saline and omeprazole treated SJL/J mice. No significant differences were observed between groups (n = 15 for the omeprazole group and n = 16 for the saline group at the start of the study, with 5 mice per group sacrificed at Day 15 and used for splenocyte analysis, above). Rotarod latency plotted vs. clinical scores during active disease, Day 14 post-encephalitogen (E) and remission, Day 21 post-encephalitogen (F). No differences were observed following omeprazole treatment vs. saline at either disease stage. A negative correlation was observed between clinical score and rotarod latency on Day 14 post-encephalitogen (r² = -0.653, p < 0.005).